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Introduction: Current diagnostic criteria for Sjogren’s syndrome developed by the American College of Rheumatology
include the presence of antinuclear antibodies, rheumatoid factor, anti-Ro or anti-La autoantibodies. The purpose of this
report is to describe two patients with biopsy-proven Sjogren’s syndrome lacking these autoantibodies but identified
by antibodies to salivary gland protein 1. Diagnosis was delayed until salivary gland tumors developed in these patients
because of the lack of the classic autoantibodies. This report emphasizes the existence of patients with primary Sjogren’s
syndrome who lack autoantibodies anti-Ro or anti-La and may therefore be misdiagnosed. Antibodies to salivary gland
protein 1 identify some of these patients.
Case presentation: Two patients are described and were seen in the autoimmune disease clinics of the State University
of New York (SUNY) at the Buffalo School of Medicine. In both patients, chronic dry mouth and dry eye had been
dismissed as idiopathic because test results for autoantibodies anti-Ro and anti-La were negative. Both patients had
swelling of major salivary glands that prompted biopsies. Biopsies of major salivary glands from both cases demonstrated
salivary gland tumors and existence of inflammation consistent with Sjogren’s syndrome. Serologic testing revealed
antibodies to salivary gland protein 1.
Conclusions: Patients presenting with classic clinical symptoms of dry mouth and eyes do not always show the current
serologic markers of Sjogren’s syndrome, anti-Ro and anti-La. In these cases, investigation for antibodies to salivary gland
protein 1 is of importance to make the diagnosis of Sjogren’s syndrome. Early diagnosis of Sjogren’s syndrome is necessary
for improved management as well as for vigilance regarding potential complications, such as salivary gland tumors as were
seen in the described cases.Introduction
Sjogren’s syndrome (SS) is an autoimmune disease that
starts in the salivary and lachrymal gland but eventually
involves multiple other organs including the lungs, kid-
neys and nervous system. It exists in 0.5 to 3 percent of
the population, but as many as 75 percent of the patients
may be missed because either they do not seek medical at-
tention and/or their physicians do not look for it. Further-
more, many patients may not meet all the current
diagnostic criteria. The most serious complication of SS is
salivary gland and gastrointestinal tumors, most com-
monly B cell lymphomas, which develop in approximately
5 percent of patients. The current diagnostic criteria for* Correspondence: jambrus@buffalo.edu
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three of four objective criteria or four of six total criteria
that include: (1) ocular symptoms, (2) oral symptoms, (3)
ocular signs, (4) focal sialoadenitis, (5) salivary gland
involvement, (6) antinuclear antibodies (ANA), rheuma-
toid factor (RF), anti-Ro or anti-La autoantibodies in the
absence of head and neck radiation treatment, hepatitis C,
acquired immunodeficiency syndrome (AIDS), sarcoid-
osis, graft versus host disease or anticholinergic drugs [1].
Diagnostic criteria are currently being reassessed as they
tend to miss the patients with early disease who are most
amenable to beneficial therapies.Case presentations
Case 1
A 60-year-old Caucasian woman presented to our
Rheumatology Clinic with complaints of persistent dry
mouth, dry eyes and a painful swelling of the left side ofntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Pleomorphic adenoma in the parotid gland with
multiple lymphocytic foci in the surrounding tissue consistent
with Sjogren’s syndrome (hematoxylin and eosin, original
magnification 4×).
Figure 2 Lymphocytic proliferation in the parotid gland affecting
the glandular elements (hematoxylin and eosin, original
magnification 40×).
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for 18 years but the more severe symptoms developed
over the period of six months prior to being seen. Periodic
serology studies for ANA, anti-Ro and anti-La were all
negative. Had she been assessed for SS, she would have
met only two criteria for SS based on ocular symptoms
and ocular signs. She developed swelling on the left side
of her neck that prompted her to visit her physician. At
that time, the evaluating physician noted a swollen sub-
mandibular gland and cervical lymphadenopathy. She had
a partial submandibular gland resection along with an
excisional biopsy of the lymph node, which was then
determined to be ‘nonspecific inflammation’. Her symp-
toms of dryness of mouth persisted and she developed
dryness of her eyes requiring the use of artificial tears six
years before her presentation to our clinic. She had no co-
morbidities at the time of her initial presentation. The
family history was notable for a sister with celiac sprue
and antiphospholipid antibodies.
A clinical examination showed dry eyes, dry mouth
and mild swelling of the left submandibular and parotid
glands. Her laboratory evaluation included a normal
complete blood count, comprehensive metabolic profile
and urinalysis. ANA, anti-Ro and anti-La test results
were all negative. A lip biopsy was also performed and
showed nonspecific inflammation of the minor salivary
glands. Additional evaluations revealed the presence of
antiphospholipid antibodies and antibodies to salivary
gland protein 1 (Sp1).
Our patient had subsequent resection of the left parotid
gland. The histology showed pleomorphic adenoma of the
left parotid gland and lymphocyte-predominant inflamma-
tion, consistent with Sjogren’s syndrome (Figure 1).
Case 2
A 63-year-old Caucasian woman presented to our
Rheumatology Clinic with complaints of persistent dry
mouth, dry eyes and swelling on the right side of her
eye. The swelling had been present for three months.
She had had a four-year history of dry eyes and dry
mouth. Her primary physician ordered anti-Ro and anti-
La antibody tests on two occasions, both of which were
negative. She would have met two criteria for SS at this
time, ocular symptoms and oral symptoms. She was
treated with artificial tears and oral liquids. After two
years, she developed swelling in her right orbital region
and progressive droopiness of her right eyelid. An exci-
sion biopsy of this mass showed non-Hodgkin lymph-
oma of the lachrimal gland. She subsequently developed
swelling of both of her parotid glands, her left more than
her right. A positron emission tomography (PET) scan
was done that revealed increased uptake in both parotid
and submandibular glands. She underwent an excisional
biopsy of the left parotid gland. Histological evaluationof the tissue revealed a marginal zone lymphoma that
was CD20+, CD23+ and CD10-. Areas of lymphocytic
infiltration were noted consistent with a diagnosis of SS
that prompted the consultation in our clinic (Figure 2).
On presentation to our clinic, she was noted to also
have a past medical history of paroxysmal nocturnal
hemoglobinuria, hepatitis C secondary to multiple blood
transfusions, hypoparathyroidism, celiac sprue, intersti-
tial cystitis, Raynaud’s phenomenon and three previous
miscarriages. Previous workup for antiphospholipid anti-
bodies was negative. Our patient was referred to us for
postsurgical follow-up and management. On physical
evaluation, she was noted to have dry mouth, livedo reti-
cularis and postsurgical scars. Her laboratory evaluation
in our clinic included tests for ANA, anti-Ro and anti-
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formed and was positive.
Discussion
Sjogren’s syndrome is a systemic autoimmune disease
starting in the salivary and lachrymal glands but eventu-
ally including involvement of multiple other organs. SS
can also occur secondary to other autoimmune diseases,
such as lupus, and rheumatoid arthritis [2]. Patients with
SS, typically present with a dry, gritty sensation in the
eyes and dry mouth. At this stage, there has already been
significant destruction of the salivary and lachrymal
glands. There is in fact a high frequency of SS in patients
with dry eyes that is frequently missed [3,4]. Typically,
involvement of the lachrymal and submandibular glands
occurs before involvement of the parotid glands. De-
struction of the sublingual glands is unusual. Lung and
kidney disease tend to occur late in the disease process.
As many as 5 percent of patients with SS develop B cell
lymphoma, most commonly occurring in the salivary
glands and gastrointestinal tract [5]. One of our patients
developed B cell lymphoma.
Many investigators utilize diagnostic criteria for SS based
on the revised American-European Consensus Group
which include (1) ocular symptoms, (2) oral symptoms, (3)
ocular signs, (4) focal sialoadenitis, (5) salivary gland
involvement, (6) anti-Ro/La antibodies in the absence of
head and neck radiation treatment, hepatitis C, AIDS, pre-
existing lymphoma, sarcoidosis, graft versus host disease
or anticholinergic drugs. Diagnosis is based on meeting
three of four objective criteria or four of six total criteria
[6]. The recent American College of Rheumatology classi-
fication criteria for diagnosis of SS also includes ANA and
RF along with anti-Ro and/or anti-La autoantibodies. The
only objective findings included are labial salivary gland
biopsy exhibiting focal lymphocytic sialoadenitis with a
focus score ≥1 focus/4 mm2 and keratoconjunctivitis sicca
with an ocular staining score ≥3 [1]. Our patients lacked
ANA, RF and anti-Ro or anti-La antibodies and were
minor salivary gland (lip) biopsy negative. They would not
have fulfilled the diagnostic criteria of SS on presentation.
The autoantibodies that are most commonly believed
to be associated with SS are anti-Ro and anti-La. How-
ever, there are multiple other antibodies that are being
studied including antibodies to muscarinic receptor 3,
tissue kallikrein, alpha-fodrin, carbonic anhydrase II and
VI, parotid-specific protein and Sp1. The significance of
these autoantibodies has not been fully appreciated [7].
As SS is typically identified at later stages, it has been
difficult to study the early events occurring in humans.
An animal model that faithfully reproduces the features
of SS seen in patients, the interleukin 14 alpha trans-
genic (IL14αTG) mouse, has been used to study early
events in the disease [8-12]. The use of this animalmodel led to the discovery of the autoantibodies to Sp1,
carbonic anhydrase VI (CA6) and parotid secretory pro-
tein (PSP). The presence of these autoantibodies in the
sera of patients with SS has been confirmed [11]. As per
these studies, only 25 percent of the IL14αTG mice
developed anti-Ro/La antibodies. Interestingly, the time
course in the development of the autoantibodies showed
that the Sp1 and CA6 antibodies were present very early
in the disease, while antibodies to Ro/La occurred late in
the disease [11]. In unpublished studies, antibodies to
Sp1 and CA6 were found in less than 5 percent of
normal controls and patients with rheumatoid arthritis
lacking secondary SS [13].
The clinical presentation of both our patients was very
typical for SS. Our first patient initially had symptoms of
dry mouth and dry eyes, then had submandibular gland
involvement, followed by parotid gland involvement. She
ultimately developed pleomorphic adenoma, a benign
salivary gland tumor. Our second patient had dry eyes
and dry mouth for multiple years followed by lymphoma
of the lachrymal and parotid glands. Neither patient had
antibodies anti-Ro or anti-La, nor did their minor saliv-
ary gland biopsies show classic features of SS. Only the
development of tumors in these cases necessitated major
salivary gland resections. Both the major salivary gland
tissues showed classic histological features of SS in
addition to the tumors.
These cases stress the importance of using autoanti-
bodies besides anti-Ro and anti-La in the diagnosis of
SS. In these patients, the presence of anti-Sp1 antibody
helped in the diagnosis of SS. We did not have early sera
to evaluate so we cannot determine when in the time
course of these patients the antibodies to Sp1 occurred,
but we suspect that they should have been present at an
early time point in the disease. The presence of these anti-
bodies was noted even before the presence of lymphocytic
infiltration of the gland in the animal model for SS that
we utilized [11]. There are likely many patients with SS
who lack autoantibodies anti-Ro or anti-La. Investigation
for antibodies to Sp1 and other markers such as CA6 and
PSP will help in the diagnosis of the patients.
The current management of SS is mostly symptomatic.
By the time of diagnosis, there is almost complete de-
struction of the salivary glands. The earlier detection of
SS with these autoantibodies may allow the development
of new forms of therapy that can preserve the function
of the salivary and lachrymal glands.
Conclusions
These cases illustrate the existence of a novel autoanti-
body, anti-salivary gland protein (Sp1), which identifies
certain patients with SS who lack autoantibodies anti-Ro
or anti-La. In each case, dry eyes and dry mouth sug-
gested the possibility of SS that was discounted because
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ary glands led to biopsies that demonstrated features of
SS. Both patients had antibodies to Sp1. Patients with
features of SS who lack antibodies anti-Ro or anti-La
should be evaluated for antibodies to Sp1. Early identifi-
cation of patients with SS will ultimately lead to better
therapies that will hopefully prevent the development of
salivary gland malignancies.
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